BioCentury
ARTICLE | Clinical News

CDX-301: Phase I started

January 23, 2012 8:00 AM UTC

Celldex began an open-label, dose-escalation, U.S. Phase I trial to evaluate 1-75 mg/kg IV or subcutaneous CDX-301 for 5-10 days in about 30 healthy volunteers. Celldex has exclusive rights to develop...